Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 13;15(1):2153409. doi: 10.1080/19420862.2022.2153409

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Binding, blocking and T cell activating characteristics of JS007. (a) Flow cytometry-based assay to test the binding between JS007 and CTLA-4, with serially diluted JS007 proteins to stain CHO cells stably expressing CTLA-4. (b) SPR analysis of the binding profiles between JS007 and CTLA-4. (c) Flow cytometry-based blocking assay to analyze the blocking of CD80-mFc protein to CHO cells stably expressing CTLA-4, with serially diluted JS007 proteins added. The binding and blocking of ipilimumab was tested in parallel as control, whereas human IgG1 isotype was analyzed as negative control. (d) Enhanced IL-2 production of T cells stimulated with allogeneic human dendritic cells in the presence of varied concentrations of JS007 as indicated. The concentration of IL-2 was measured with ELISA assay. Stimulation with serial dilutions of ipilimumab or human IgG1 isotype control were also enrolled as controls. Statistical analysis was calculated with student’s T test. ***, p < .001; **, p < .01; *, p < .05; ns, p > .05.